New oral combo aims to keep leukemia at bay after remission

NCT ID NCT05010772

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This phase 1 trial tests an oral chemotherapy drug (decitabine) alone or combined with other targeted drugs to prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. About 125 adults whose AML is under control but who are not ready for a stem cell transplant will take the medication by mouth. The main goal is to check safety and side effects, while also seeing how long patients stay cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Decitabine and Cedazuridine (ASTX727), with optional Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib
What this could lead to: If successful, this could provide a convenient oral maintenance option to keep AML in remission longer and delay or avoid relapse.
What could go wrong: This is an early phase 1 trial focused on safety, so it is too soon to know if it works. Side effects from the drug combinations are possible, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.